INTRODUCTION

Debridement
and prosthesis retention, combined with a prolonged antibiotic regimen including rifampicin, is an accepted therapeutic approach when the duration of symptoms is less than 4 weeks and there are no radiological signs of loosening. The outcome of patients managed with this strategy has been previously assessed in several articles with success rates between 60% and 90% [1] [2] [3] [4] [5] [6] . The best results have been reported when rifampicin was associated with fluoroquinolones [4, 5] ; however, the rate of multi-resistant staphylococci, including fluoroquinolones, is high and therefore, oral antibiotic alternatives are necessary. Linezolid has a 100% oral bioavailability and reaches high concentrations in musculoskeletal tissues (skin, synovial fluid and bone) [7] [8] [9] ; therefore, it is an attractive oral alternative and some data from experimental foreign-body infection model showed good results [10] . Recently, two studies performed in healthy volunteers have analyzed the interaction between linezolid and rifampicin after 3 days of combined therapy [11, 12] . Both articles support the interaction and found a reduction of about 30% in the area under the concentration-time curve (AUC) of linezolid. In addition, 2 cases of orthopedic implant infections where this combination was associated with low linezolid serum concentrations and clinical failure have been described [13] . However, the clinical experience with this combination is still scarce.
The aim of the present study was to 
METHODS
Study Design
A retrospective observational study was performed in 3 hospitals from Barcelona, Outcome was classified according to the following definitions: (1) remission, when the patient had no symptoms of infection, the C-reactive protein (CRP) was \1 mg/dl and the prosthesis was retained after at least 1 year of follow-up; or (2) 
RESULTS
A total of 39 patients were retrospectively reviewed. The mean age (SD) was 70.5 (8.8) years, 21 were females (54%) and 9 patients had diabetes mellitus (23%). There were 25 (64%) knee prostheses, 13 (33%) hips and 1 shoulder (3%). Only 4 (10%) were late acute infections.
The median (IQR) days from arthroplasty to infection diagnosis was 17 and 33 (85%) cases were diagnosed within the first 60 days.
Infections were monomicrobial in 24 (62%) cases and polymicrobial in 15 (38%), and the isolated microorganisms are described in CoNS were in remission (58%) and 7 (27%) were due to infection relapse. The cumulative probability of being in remission in the last visit in patients receiving or not rifampicin is shown in Fig. 1 (Log-Rank test, P = 0.25). There were no differences in the total number of AEs between both groups; however, gastrointestinal complains were more frequent in the rifampicin group (32% vs. 18%) while hematological toxicity was more frequent in the group without rifampicin (24% vs. 5%).
DISCUSSION
An alternative agent for treating PJIs due to fluoroquinolone-resistant staphylococci is necessary [14] . In the present study, acute PJIs were managed with debridement, retention of the implant and linezolid with a remission rate of 72% and when considering only relapses (isolation of the same species), it was 80%. These results are similar to those presented by Bassetti et al. [15] using the same surgical strategy and linezolid alone in 20 PJIs with a New infection 2 (9) 1 (6) remission rate of 80% and 20% of relapsing infections. Monotherapy with linezolid was also evaluated by Rao et al. [16] in 11 cases with a remission rate of 95%. Although the experience is limited, these results are in contrast to the 23% remission rate described using intravenous vancomycin in MRSA PJI treated with retention of the implant [17] and it suggests that linezolid could be an alternative for infections due to multi-resistant staphylococci.
The addition of rifampicin to linezolid would be reasonable [18, 19] , particularly when the foreign-body is not removed, due to the potent activity of rifampicin against biofilm bacteria [4, 20] . It has been demonstrated that rifampicin reduces about 30% the AUC of linezolid [11, 12] ; however, the clinical implication of this interaction is not well established. This combination was assessed in a retrospective study that reviewed 28 osteomyelitis and Fig. 1 The cumulative probability of being in remission according to whether the patient received concomitant rifampicin or not (Log-Rank test, P = 0.25) [25] , the optimal trough level will be 4 mg/L, a concentration that also it has been associated with low risk of toxicity [26] , which is the major concern when linezolid is administered for prolonged time. These results suggest that monitoring trough serum concentration could be useful for improving the outcome, most especially when linezolid is combined with rifampicin, and for avoiding toxicity in patients that require prolonged treatment [27] . Indeed, hematological toxicity was more frequent in the monotherapy group (24% vs. 5%) probably due to the higher linezolid concentrations.
The main drawbacks of this study are the 
